All
This Wasn’t the Plan: My Mother and Her Silence
In part 4, the author reflects on her mother’s silent strength and unwavering love during her cancer journey, as she cared for her daughter while silently battling her own illness.
Veteran Credits CAR T-Cell Therapy With Helping Him Reach Remission
Mark Daniels, 83, says CAR T-cell therapy and strong support helped him overcome lymphoma twice and return to the fitness-focused life he values.
Tipping My Hat to the Heroes of the Cancer Community
Tamron Little was diagnosed with peritoneal mesothelioma in 2007 as a 21-year-old new mother. Catch up on Tamron's blogs here!
FDA Grants Accelerated Approval to Lynozyfic for Multiple Myeloma
The FDA approved Lynozyfic for relapsed multiple myeloma, but serious risks require restricted use under a special safety program.
Living After Cancer: A Cancer Thriver Shares Her Story
Valarie Traynham, a cancer thriver and patient advocate, imparts advice and discusses survivorship after a cancer diagnosis.
Temferon Linked to Long-Term Survival in Some With Glioblastoma
Two glioblastoma patients treated with Temferon have lived 3 years post-surgery; one had no progression, the other stabilized after initial progression.
A Cancer Survivor Calls Beating the Disease a ‘World Championship’
Daniel Jernazian, who beat cancer twice, credits his sports mindset for survival and calls it winning his ‘life World Championship’.
This Wasn’t the Plan: I Lost My Hair, Not My Fire
In part 3 of “This Wasn’t the Plan,” a young woman reflects on her father’s strength during his illness and how, after her own diagnosis, their bond became her greatest source of courage.
Social and Economic Barriers May Affect Outcomes in Blood Cancers
Patients in rural or underserved areas may have worse outcomes, highlighting the need for early support to address care access barriers.
Survival, Symptoms and Support in Waldenström Macroglobulinemia
Waldenström macroglobulinemia is often slow growing, with a 78% five-year survival rate, but chronic conditions can affect quality of life over time.
Therapies Which Received FDA Approval in July: What You Should Know
Breaking down what patients should know about each FDA therapeutic approval from June 2025 across various oncology indications and cancer types.
A Cocktail and the Freedom I Never Expected With Cancer
After years off medication, I finally enjoyed a grapefruit cocktail — symbolizing freedom from cancer’s constant shadow and hope for the future.
Leronlimab Shows Activity in Advanced Metastatic Colorectal Cancer
Three of five patients with advanced colorectal cancer responded to leronlimab, including one complete response lasting five years, according to new data.
The Utility of CAR T-Cell Therapy in Myelofibrosis
Dr. Matthew Ku discusses what CAR T-cell therapy is and how it works to target diseases like myelofibrosis.
This Wasn't the Plan: The Truth
In part 2 of “This Wasn't the Plan,” a young woman recalls her stage 4 blood cancer diagnosis and how chemotherapy revealed unexpected reserves of strength.
Living With Intention After a Cancer Diagnosis
Valarie Traynham discusses some of ways her life has changed since being diagnoses with cancer, and what parts of her identity have remained the same.
June Lung Cancer Highlights: Top 5 Updates Patients Should Know
During June, investigators reported new data that has advanced the treatment landscape for lung cancer, including new FDA approvals and priority reviews.
Could Shedding a Few Pounds Prevent a Breast Cancer Recurrence?
After years of survivorship, I’m realizing that shedding extra pounds may do more than improve comfort — it could reduce my risk of recurrence.
The Hidden Cost of Cancer: Time Toxicities and Insurance Delays
Dr. Alexandra Zaleta discusses how most cancer patients face prior authorization delays, despite 95% being approved, highlighting the need for reform.
What is on the Horizon for Kidney Cancer?
Dr. Emre Yekedüz discusses how ASCO 2025 highlights precision medicine, biomarkers and the gut microbiome as keys to advancing kidney cancer care.
GIST Expert Urges Patients to Seek Specialized Second Opinions
Dr. Breelyn Wilky stresses the importance of expert guidance and second opinions for patients with GIST, as treatment options continue to evolve rapidly.
Living with Cancer Taught Me Strength, Wage Theft Taught Me Silence
Diagnosed with incurable cancer in her 20s, Nathalie Jean rebuilt broken systems in public service — only to face wage theft and silence after success.
What Does National Cancer Survivors Month Mean to You?
CURE asked cancer survivors, thrivers, advocates, and those whose lives have been touched by cancer: what does National Cancer Survivors Month mean to you?
June GU Cancer Highlights: Top 5 Updates Patients Should Know
June brought genitourinary cancer updates, and CURE is sharing the latest in kidney cancer treatment, as well as FDA approvals, cancer vaccines and more.
This Wasn't the Plan: When the World Shifted After Cancer
At age 19, I was a medical student with big dreams — until stage 4 blood cancer changed everything, leading to a journey of resilience and quiet hope.
A Reflection on Hope from a Cancer Survivor
I share how hope, even when uncertain, helped me through cancer and honors its role in balancing realism, resilience and emotional survival.
A Veteran Reflects on CAR T-Cell Therapy and Isolation
Mark Daniels, 83, credits CAR T-cell therapy and compassionate care for helping him overcome lymphoma and endure the isolating treatment toll.
June Prostate Cancer Highlights: Top 5 Updates Patients Should Know
June brought major prostate cancer updates, and CURE is sharing the latest FDA approvals, label expansions, and emerging data on the role of AI in care.
Saying No to Shapewear After a Double Mastectomy
After having a double mastectomy to rid myself of cancer, I’m less picky about how I look and won’t be wearing uncomfortable shapewear for a wedding.
FDA Approves CAR T Therapy Label Updates Across Various Blood Cancers
Label updates have been approved by the FDA for the CAR T-cell therapies Breyanzi and Abecma in large B cell lymphoma and multiple myeloma, respectively.